Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMN-001 + Standard Treatment in Advanced Renal Cell Carcinoma
NCT04203901Phase 2Terminated
- Sponsor
- CoImmune, Inc.
- Start
- Jul 2020
- Primary completion
- Sep 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of rocapuldencel-T in renal cell carcinoma (RCC), sponsored by CoImmune, Inc.. Started Jul 2020; status: terminated.
02
Drugs
rocapuldencel-T
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04203901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203901.